Format

Send to

Choose Destination
See comment in PubMed Commons below
FEBS Lett. 2012 May 21;586(10):1397-402. doi: 10.1016/j.febslet.2012.03.052. Epub 2012 Apr 3.

Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy.

Author information

1
Comparative Oncology Laboratory, University of California, Davis, CA 95616, USA.

Abstract

The ubiquitin-dependent proteasome system plays a critical role in many cellular processes and pathogenesis of various human diseases, including cancer. Although there are a large number of E3 ubiquitin ligases, the majority are RING-finger type E3s. Pirh2, a target of p53 transcription factor, contains a highly conserved C(3)H(2)C(3) type RING domain. Importantly, Pirh2 was found to regulate a group of key factors dedicated to the DNA damage response, such as p53, p73, PolH, and c-Myc. Interestingly, Pirh2 was upregulated or downregulated in different types of cancers. These suggest that Pirh2 is implicated in either promoting or suppressing tumor progression in a tissue-dependent manner. This review will focus on the major findings in these studies and discuss the potential to explore Pirh2 as a cancer therapeutic target.

PMID:
22673504
PMCID:
PMC3372855
DOI:
10.1016/j.febslet.2012.03.052
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center